J Korean Med Sci.  2023 Jun;38(24):e209. 10.3346/jkms.2023.38.e209.

New-Onset Fulminant Type 1 Diabetes Following SARS-CoV-2 Protein Subunit Vaccine: A Case Report and Literature Review

• Huang L
• Liang M
• He Y

• KMID: 2543978
• DOI: http://doi.org/10.3346/jkms.2023.38.e209

Abstract

The ravages of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) worldwide have sped up the development of relevant vaccines, which is accompanied by public concerns over possible adverse effects. We report a rare case of a 39-year-old woman who suffered from severe hyperglycemia and ketoacidosis with normal hemoglobin A1c four days after SARS-CoV-2 protein subunit vaccine, which is consistent with the diagnosis of fulminant type 1 diabetes (FT1D). She received insulin therapy and recovered after 24 days from onset of the symptoms. This is the first case of new-onset FT1D after SARS-CoV-2 protein subunit vaccination and one of only six that developed after any form of SARS-CoV-2 vaccination. We hope to raise awareness of this potential adverse consequence and recommend careful monitoring after vaccination in patients even without a medical history of diabetes.

Keyword

Fulminant Type 1 Diabetes; SARS-CoV-2 Vaccine; Protein Subunit Vaccine; Adverse Effects

Reference

1. Forgacs D, Silva-Moraes V, Sautto GA, Hanley HB, Gattiker JL, Jefferson AM, et al. The effect of waning on antibody levels and memory B cell recall following SARS-CoV-2 infection or vaccination. Vaccines (Basel). 2022; 10(5):696. PMID: 35632452.

2. World Health Organization. COVID-19 vaccine tracker and landscape. Accessed February 7, 2023. https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines. Updated 2023 .

3. Patrizio A, Ferrari SM, Antonelli A, Fallahi P. A case of Graves’ disease and type 1 diabetes mellitus following SARS-CoV-2 vaccination. J Autoimmun. 2021; 125:102738. PMID: 34653776.

4. Rela M, Jothimani D, Vij M, Rajakumar A, Rammohan A. Auto-immune hepatitis following COVID vaccination. J Autoimmun. 2021; 123:102688. PMID: 34225251.

5. Vuille-Lessard É, Montani M, Bosch J, Semmo N. Autoimmune hepatitis triggered by SARS-CoV-2 vaccination. J Autoimmun. 2021; 123:102710. PMID: 34332438.

6. Garrido I, Lopes S, Simões MS, Liberal R, Lopes J, Carneiro F, et al. Autoimmune hepatitis after COVID-19 vaccine - more than a coincidence. J Autoimmun. 2021; 125:102741. PMID: 34717185.

7. Sagy I, Zeller L, Raviv Y, Porges T, Bieber A, Abu-Shakra M. New-onset systemic lupus erythematosus following BNT162b2 mRNA COVID-19 vaccine: a case series and literature review. Rheumatol Int. 2022; 42(12):2261–2266. PMID: 36098769.

8. Sakurai K, Narita D, Saito N, Ueno T, Sato R, Niitsuma S, et al. Type 1 diabetes mellitus following COVID-19 RNA-based vaccine. J Diabetes Investig. 2022; 13(7):1290–1292.

9. Lin R, Lin YW, Chen MH. Fulminant type 1 diabetes mellitus after SARS-CoV-2 vaccination: a case report. Vaccines (Basel). 2022; 10(11):1905. PMID: 36423001.

10. Kobayashi T, Yakou F, Saburi M, Hirose A, Akaoka H, Hirota Y, et al. New-onset atypical fulminant type 1 diabetes after COVID-19 vaccination: a case report. Clin Case Rep. 2022; 10(10):e6473. PMID: 36267825.

11. Sasaki K, Morioka T, Okada N, Natsuki Y, Kakutani Y, Ochi A, et al. New-onset fulminant type 1 diabetes after severe acute respiratory syndrome coronavirus 2 vaccination: a case report. J Diabetes Investig. 2022; 13(7):1286–1289.

12. Tang X, He B, Liu Z, Zhou Z, Li X. Fulminant type 1 diabetes after COVID-19 vaccination. Diabetes Metab. 2022; 48(2):101324. PMID: 35091092.

13. Chee YJ, Ng SJ, Yeoh E. Diabetic ketoacidosis precipitated by Covid-19 in a patient with newly diagnosed diabetes mellitus. Diabetes Res Clin Pract. 2020; 164:108166. PMID: 32339533.

14. Fadini GP, Morieri ML, Boscari F, Fioretto P, Maran A, Busetto L, et al. Newly-diagnosed diabetes and admission hyperglycemia predict COVID-19 severity by aggravating respiratory deterioration. Diabetes Res Clin Pract. 2020; 168:108374. PMID: 32805345.

15. Liao HC, Wu WL, Chiang CY, Huang MS, Shen KY, Huang YL, et al. Low-dose SARS-CoV-2 S-trimer with an emulsion adjuvant induced th1-biased protective immunity. Int J Mol Sci. 2022; 23(9):4902. PMID: 35563292.

16. Silveira MM, Moreira GM, Mendonça M. DNA vaccines against COVID-19: perspectives and challenges. Life Sci. 2021; 267:118919. PMID: 33352173.

17. Ibrahim S, Monaco GS, Sims EK. Not so sweet and simple: impacts of SARS-CoV-2 on the β cell. Islets. 2021; 13(3-4):66–79. PMID: 33970787.

18. Drucker DJ. Diabetes, obesity, metabolism, and SARS-CoV-2 infection: the end of the beginning. Cell Metab. 2021; 33(3):479–498. PMID: 33529600.

19. Yang S, Li Y, Dai L, Wang J, He P, Li C, et al. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials. Lancet Infect Dis. 2021; 21(8):1107–1119. PMID: 33773111.

20. Tran TN, May BP, Ung TT, Nguyen MK, Nguyen TT, Dinh VL, et al. Preclinical immune response and safety evaluation of the protein subunit vaccine Nanocovax for COVID-19. Front Immunol. 2021; 12:766112. PMID: 34938290.

21. Lui DT, Lee KK, Lee CH, Lee AC, Hung IF, Tan KC. Development of Graves’ disease after SARS-CoV-2 mRNA vaccination: a case report and literature review. Front Public Health. 2021; 9:778964. PMID: 34888290.

22. Oikawa Y, Shimada A. Possible involvement of autoimmunity in fulminant type 1 diabetes. Diabetol Int. 2020; 11(4):329–335. PMID: 33088639.

23. Luo S, Ma X, Li X, Xie Z, Zhou Z. Fulminant type 1 diabetes: a comprehensive review of an autoimmune condition. Diabetes Metab Res Rev. 2020; 36(6):e3317. PMID: 32223049.

24. Imagawa A, Hanafusa T, Miyagawa J, Matsuzawa Y. Osaka IDDM Study Group. A novel subtype of type 1 diabetes mellitus characterized by a rapid onset and an absence of diabetes-related antibodies. N Engl J Med. 2000; 342(5):301–307. PMID: 10655528.